In 2012 you can meet with us at:
Meet the CEO and Chairman at Cell Line Development & Engineering Asia 2012, February 20-23, Shanghai, China.
Events 2011:
Presented at swissnex-SIMTech event, September, Singapore. Topic: Chief Scientist, Dr. Lilli Brandtner presented at the Swiss-Singapore Workshop on Microfluidics which was organised and supported by swissnex and held at A*STAR’s SIMTech institute at Nanyang Technical University in Singapore. The meeting concerned industry developments in the area of microfulidics.
Chief Scientist, Dr. Lilli Brandtner at the swissnex-SIMTech event
Displayed at BioKorea, September 28-30, COEX, Seoul, Korea. Topic: BioKorea is one of Asia’s most important Biotech events, covering a diverse range of applications and areas such as medical care, food, agriculture, energy, chemical, and the environment.
BioKorea Sept 2011: Chief Scientist, Dr Lilli Brandtner at the SG Austria stand
Sponsored and Presented at: Phacilitate’s Cell and Gene Therapy Forum Asia, September 19-21, Singapore. Topic: COO, Dr John Dangerfield presented in the plenary session “How can the global cell and gene therapy sector address Asia’s most unmet medical needs”. He also chaired and took part in the panel discussion for the focus session on international funding and commercialisation opportunities for Asian cell and gene therapy companies. Dr Stephen Rhind, a consultant to SG Austria, also attended on their behalf.
Cell and GT Forum, Sept 2011. COO, Dr John Dangerfield during chairing of the focus session
Displayed at: Bio International Convention 2011, June 27-30, Washington DC, U.S.A. Topic: SG Austria had a attractively designed display booth in the Singapore pavilion along with around 20 other biotech companies from Singapore supported by International Enterprises SG (IE Singapore). The event was a great success with a permanent stream of interested visitors.
The BIO, June 2011. COO Dr John Dangerfield at the SG Austria display stand
Presented at: Cell Therapy Summit Europe 2011, March, Maastrict, Natherlands. Topic: An exclusive gathering of CEOs, investors, academic researchers and other high-level executives examined what it takes to create a successful business and establish a path forward for the mostly uncharted territory of cell therapy.
Invited to: BioSpectrum Asia Pacific Awards 2011, March 16, Singapore. Topic: An afternoon of interest with expert panel members followed by an evening of achievement awards to some of Asia’s best biotech companies.
Events 2010:
Presented at: BioEurope 2010, Munich, Germany, 15-17 November. Session: The Perfect Pitch.
Presented at: Stem Cell Society, Singapore Symposium 2010, Singapore, 3 November. Topic: Cell in a Box technology: biomedical applications and clinical experience.
Presented at: CliniGene Industry satellite of the XVIII Annual Congress of the European Society of Gene and Cell Therapy, Milan, Italy, 25 October. Topic: Models for Industry development: Financing the development of gene and genetically modified cell therapies
Presented at XVIII Annual Congress of the European Society of Gene and Cell Therapy. Milan, Italy, 22 – 25 October
Presented at: Pharma Licensing Strategies Asia 2010, Singapore, 15 September 2010. Topics: ‘Cell Encapsulation Technology allowing cells to be implanted for long term therapy’ and ‘Post-Exit Surface Modification of Enveloped Viruses And Viral Vectors’.
Presented at: International Conference on Cellular & Molecular Bioengineering (ICCMB2), NTU, Singapore, 02 August. Topic: Past clinical success and new developments with live cell encapsulation for the treatment of cancer and other serious diseases
Presented at: 1st NUHS-KCL Gene Therapy, NUS, Singapore 05 March. Topic: Gene and cell therapies for cancer- different strategies and clinical experiences.
